News Archive

31 Aug. 2021

Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study

Aposcience AG received the Recommendations of the Data Safety Monitoring Board (DSMB). On 30 July 2021, three experts in the field of wound healing, after revising the data of the Lead In-Phase of the MARSYAS II trial (EudraCT...[more]

27 May. 2021

Approval for clinical phase II study in DFU by German health agency PEI

On 27 May 2021 Aposcience AG received the notification of the Paul-Ehrlich-Institut of the approval of the clinical phase II trial in diabetic foot ulcer (DFU), MARSYAS II, for Germany. Currently, the MARSYAS II trial has...[more]

12 Dec. 2019

Approval for clinical phase II study in DFU by Austrian health agency

Aposcience AG was granted approval by the Austrian health agency BASG to start a clinical phase II study in the indication diabetic foot ulcers of its novel product APOSEC, the secretome of stressed Peripheral Blood Mononuclear...[more]

10 Oct. 2019

US Patent Office issues Allowance for APOSEC Patent

On Sept. 6, 2019, the United States Patent and Trademark Office issued a Notice of Allowance concerning the US patent application No. 13/140,120 "Pharmaceutical preparation", the patent of APOSEC for the treatment of internal...[more]

31 Mar. 2016

MarsyasI - clinical phase 1 study completed

Maryas I - clinical phase 1 study was completed on 5 February 2016[more]

24 Nov. 2015

Paper on content analysis of APOSEC recently published

Beer L et al. Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration - was recently published in Scientific Reports. Sci Rep. 2015 Nov...[more]

02 Apr. 2015

EPO intends to grant APOSEC patent for treatment of systemic conditions

The European Patent Office informed us its intention to grant our patent application for the treatment of systemic conditions with APOSEC.[more]

31 Mar. 2015

APOSEC attenuates secondary damage following spinal cord injury

New Paper accepted in Experimental Neurology[more]

23 Oct. 2014

Kickoff Meeting for Marsyas I Trial

On 23 Oct. 2014 the clinical phase I trial Marsyas I, a prospective, single-Center, randomised, double-blinded, placebo controlled, dose finding phase I study in the indication skin wound healing was initiated. The Kickoff...[more]

25 Apr. 2014

AGES Approval for APOSEC allogeneic and autologous production

On 25 April 2014 the Austrian Health Authority AGES issued the approval for the production of allogeneic and autologous APOSEC for clinical testing in the APOSEC GMP production facilty at the Blood Bank Linz.[more]

Displaying 1 to 10 of 17
<< First < Previous 1-10 11-17 Next > Last >>
Latest News
Aug
31

Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study

[more]

May
27

Approval for clinical phase II study in DFU by German health agency PEI

[more]